rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    XPH
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Which Healthcare ETF Is the Better Buy: State Street’s Pharma Fund XPH or iShares’ Biotech Fund IBB? | The Motley Fool

      XPH charges less and pays a higher yield, but IBB manages over 20 times the assets across a far broader set of research-driven biotech names.

      Nov 15The Motley FoolIBBSTTXPH
      Which Healthcare ETF Is Best for the Long Term: State Street’s XPH or Invesco’s PBE? | The Motley Fool

      Lower fees and a steadier beta set one healthcare ETF apart, while the rival fund's richer dividend could sway income-focused investors.

      Nov 15The Motley FoolIVZSTTXPH
      Drug Makers or Biotech Bets: Which ETF Is the Better Buy, State Street’s XPH or First Trust’s FBT? | The Motley Fool

      One fund holds about 60 drug companies at a lower fee. The other holds 30 biotech names and has a stronger long-term record. Either way, expect some volatility.

      Nov 11The Motley FoolSTTFBTXPH
      Can GLP-1s Fatten Your Portfolio? We Examine the VanEck Pharmaceutical ETF vs State Street SPDR Pharmaceuticals ETF | The Motley Fool

      VanEck's concentrated 26-stock portfolio delivered stronger five-year returns and lower volatility, while State Street's 62-holding fund offers broader diversification and lower fees.

      Oct 30The Motley FoolXPH
      Which Healthcare ETF Is the Better Buy: State Street’s Pharma XPH or Simplify’s Mission-Driven PINK? | The Motley Fool

      Active management and a philanthropic mission set Simplify apart, though State Street's lower costs and stronger recent returns appeal to passive investors.

      Oct 26The Motley FoolSTTPINKXPH
      Is State Street SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

      Smart Beta ETF report for XPH

      Oct 21Yahoo FinanceSTTXPH
      XPH: Healthcare Sector Dashboard For October (NYSEARCA:XPH)

      SPDR S&P Pharmaceuticals ETF offers diversified pharma exposure with low company-specific risk due to its modified equal-weight methodology. Read more on XPH.

      Oct 16Seeking AlphaXPH
      Better Pharma ETF: iShares IHE vs. State Street XPH | The Motley Fool

      IHE concentrates 23.6% in Eli Lilly and delivers 1.4% yield, while XPH spreads risk across 62 holdings with a lower 0.35% expense ratio.

      Oct 10The Motley FoolIHEXPH
      Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma | The Motley Fool

      BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

      Oct 10The Motley FoolBBHDESKXPH
      Is State Street SPDR S&P Telecom ETF (XTL) a Strong ETF Right Now?
      Oct 5Yahoo FinanceSTTXBIXNTKXPHXRTXSDXTLXTN
      Better State Street Healthcare ETF: XBI's Biotech Focus vs. XPH Targeting Pharmaceuticals | The Motley Fool

      XPH delivered 19% higher returns over five years despite half the volatility. XBI's 165 holdings offer broader exposure but with a 53% maximum drawdown.

      Oct 4The Motley FoolSTTXBIXPH
      Is State Street SPDR S&P Semiconductor ETF (XSD) a Strong ETF Right Now?
      Sep 30Yahoo FinanceSMHSOXXSTTXBIXNTKXPHXSD
      Is State Street SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
      Sep 29Yahoo FinanceXPH
      Is State Street SPDR S&P Retail ETF (XRT) a Strong ETF Right Now?
      Sep 18Yahoo FinanceRTHSTTRSPSXARXBIXHBXNTKXPHXRTXTN
      Is State Street SPDR S&P Health Care Services ETF (XHS) a Strong ETF Right Now?

      Smart Beta ETF report for XHS

      Sep 17Yahoo FinanceSTTRSPHXESXHSXPH
      IXJ vs XPH: Global Healthcare ETF or Pharma Focus? | The Motley Fool

      XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading.

      Sep 12The Motley FoolIXJXPH
      IXJ vs XPH: Global Healthcare ETF or Pharma Focus?

      Motley Fool Press Release.

      Sep 11The Globe and MailXPH
      Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH | The Motley Fool

      Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility.

      Sep 10The Motley FoolSTTXPH
      Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? | The Motley Fool

      FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it.

      Sep 10The Motley FoolSTTFHLCXPH
      Is State Street SPDR S&P Homebuilders ETF (XHB) a Strong ETF Right Now?

      Smart Beta ETF report for XHB

      Sep 8Yahoo FinanceSTTKBEXARXBIXHBXHSXPHXRTXSD

      This is the newest page. Registered accounts read further back.